At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 70 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
PF-06651600 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate
In Brief
A Phase 2 clinical trial evaluating Placebo and PF-06651600 for Rheumatoid Arthritis. Completed, enrolled 70 participants across 30 sites in 9 countries.
Detailed Summary
This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesBulgaria, Czechia, Georgia, Germany, Hungary, Poland, Serbia, Slovakia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 2016
Enrollment StartDec 2016
Primary CompletionDec 2017
TodayJul 2026
First PostedNov 21, 2016
Enrollment StartDec 20, 2016
Primary CompletionDec 12, 2017
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 9.6 years ago
Interventions
Placebodrug
PF-06651600drug
200mg pill every day (QD) for 8 weeks